Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03UJT
|
|||
| Former ID |
DIB018207
|
|||
| Drug Name |
[3H](-)devapamil
|
|||
| Synonyms |
(-)-Desmethoxyverapamil; (-)-Devapamil; 4-Desmethoxyverapamil; UNII-99EAI85506; 99EAI85506; 93468-87-2; (2S)-2-(3,4-dimethoxyphenyl)-5-[2-(3-methoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; AC1L32ZZ; AC1Q4Q2Z; 4-DMV; (-)-H3-Desmethoxyverapamil; GTPL2515; GTPL2517; SCHEMBL10453636; 4-desmethoxyverapamil (4-DMV); ZINC2016058; PDSP2_001070; PDSP1_001086; benzeneacetonitrile, 3,4-dimethoxy-; A-(3-((2-(3-methoxyphenyl)ethyl)methylamino)propyl)-; A-(1-methylethyl)-,(s)-; D888; D 888; D-888; (-)-D888; Desmethoxyverapamil
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H36N2O3
|
|||
| Canonical SMILES |
CC(C)C(CCCN(C)CCC1=CC(=CC=C1)OC)(C#N)C2=CC(=C(C=C2)OC)OC
|
|||
| InChI |
1S/C26H36N2O3/c1-20(2)26(19-27,22-11-12-24(30-5)25(18-22)31-6)14-8-15-28(3)16-13-21-9-7-10-23(17-21)29-4/h7,9-12,17-18,20H,8,13-16H2,1-6H3/t26-/m0/s1
|
|||
| InChIKey |
VMVKIDPOEOLUFS-SANMLTNESA-N
|
|||
| CAS Number |
CAS 93468-87-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2515). | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2517). | |||
| REF 3 | (-)-[3H]Desmethoxyverapamil, a novel Ca2+ channel probe. Binding characteristics and target size analysis of its receptor in skeletal muscle. FEBS Lett. 1984 Oct 29;176(2):371-7. | |||
| REF 4 | Pharmacological, radioligand binding, and electrophysiological characteristics of FPL 64176, a novel nondihydropyridine Ca2+ channel activator, in cardiac and vascular preparations. Mol Pharmacol. 1991 Nov;40(5):734-41. | |||
| REF 5 | Role of apoptosis in the kidney after reperfusion. Orv Hetil. 2008 Feb 17;149(7):305-15. | |||
| REF 6 | Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol. 1997;37:361-96. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.